- $562.03m
- $353.73m
- $1.00m
Brief: Shattuck Labs Q4 Net Income USD -17.687 Million
Shattuck Labs Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Ono Pharmaceutical Enters Drug Discovery Collaboration & Option Agreement With Shattuck Labs
Brief: Shattuck Labs Enters Into Strategic Collaboration With Ono Pharma To Generate Bifunctional Fusion Proteins
Brief: Ono Enters Into A Drug Discovery Collaboration & Option Agreement With Shattuck Labs To Generate Bifunctional Fusion Proteins
Brief: Shattuck Labs Provides Corporate Update And Highlights Upcoming Key Milestones In 2024
Brief: Shattuck Labs Announces $50 Million Public Offering Of Common Stock And Concurrent Private Placement Of Pre-Funded Warrants
U.S. STOCKS ON THE MOVE-Xpeng, Canopy Growth, ReShape Lifesciences
U.S. STOCKS ON THE MOVE-Southwest Airlines, Canopy Growth, US Steel
U.S. STOCKS ON THE MOVE-Vertex Pharma, Shattuck Labs, Airbnb
Shattuck Labs jumps as therapy shows promise in cancers treatment trial
Brief: Shattuck Labs Announces Positive Initial Topline Data From Phase 1 A/B Dose Expansion Clinical Trial Of Sl-172154 With Azacitidine
Brief: Shattuck Labs - As Of Sept 30, 2023, Cash And Cash Equivalents And Investments $101.1 Million
Brief: Shattuck Labs Q3 Net Income USD -27.541 Million
Shattuck Labs Inc expected to post a loss of 52 cents a share - Earnings Preview
Shattuck Labs Inc reports results for the quarter ended in June - Earnings Summary
Brief: Shattuck Labs, Inc. Q2 basic EPS USD -0.5
Shattuck Labs Inc expected to post a loss of 52 cents a share - Earnings Preview
Brief: Shattuck Labs To Present Complete Dose-Escalation Data From Phase 1A Monotherapy Clinical Trial Of Sl-172154 In Platinum-Resistant Ovarian Cancer (PROC)